Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trialShuyu Ji, Yuming Zhu, Kaiqi Jin et al.|BMC Medicine|2025Cited by 6
Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable Stage IIA-IIIA NSCLC: A Multicenter, Two-Arm, Phase II Exploratory TrialShuyu Ji, Yuming Zhu, Zhenxin Sheng et al.|Research Square|2025Cited by 0